1. The Association of Lipid-Modifying Medications With Mortality in Patients on Long-Term Peritoneal Dialysis 
Alexander S. Goldfarb-Rumyantzev, MD, PhD, Arsalan N. Habib, MD, Bradley C. Baird, MS, MStat, Lev L. Barenbaum, PhD, Alfred K. Cheung, MD 
American Journal of Kidney Diseases 
Volume 50, Issue 5, Pages (November 2007)
DOI: /j.ajkd
Copyright © 2007 National Kidney Foundation, Inc. Terms and Conditions

2. Figure 1
Flow chart describing study subject selection from the US Renal Data System (USRDS) Dialysis Morbidity and Mortality (DMMS) Wave 2 file.
American Journal of Kidney Diseases  , DOI: ( /j.ajkd )
Copyright © 2007 National Kidney Foundation, Inc. Terms and Conditions

3. Figure 2
Kaplan-Meier curves show the association between use of lipid-modifying medications and (A) all-cause and (B) cardiovascular mortality.
American Journal of Kidney Diseases  , DOI: ( /j.ajkd )
Copyright © 2007 National Kidney Foundation, Inc. Terms and Conditions

4. Figure 3
Adjusted hazard ratios for all-cause mortality associated with the use of lipid-modifying medications in subgroups of patients defined by serum total cholesterol level. The plot suggests an incremental increase in the benefit of using lipid-modifying medications with increasing cholesterol levels. To convert total cholesterol in mg/dL to mmol/L, multiply by
American Journal of Kidney Diseases  , DOI: ( /j.ajkd )
Copyright © 2007 National Kidney Foundation, Inc. Terms and Conditions

5. Figure 4
Adjusted hazard ratios for all-cause (filled bars) and cardiovascular (striped bars) mortality associated with use of lipid-modifying medications in the entire study population and the diabetic subgroup. *Statistically significant (P < 0.05) difference compared with patients not using these medications (open bar).
American Journal of Kidney Diseases  , DOI: ( /j.ajkd )
Copyright © 2007 National Kidney Foundation, Inc. Terms and Conditions